
Kathryn R Wagner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11901065/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child. New England Journal of Medicine, 2004, 350, 2682-2688.	13.9	1,238
2	Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurology, The, 2018, 17, 251-267.	4.9	767
3	Developing a pro-regenerative biomaterial scaffold microenvironment requires T helper 2 cells. Science, 2016, 352, 366-370.	6.0	464
4	A phase I/Iltrial of MYOâ€029 in adult subjects with muscular dystrophy. Annals of Neurology, 2008, 63, 561-571.	2.8	407
5	Loss of myostatin attenuates severity of muscular dystrophy inmdx mice. Annals of Neurology, 2002, 52, 832-836.	2.8	351
6	Contemporary Cardiac Issues in Duchenne Muscular Dystrophy. Circulation, 2015, 131, 1590-1598.	1.6	240
7	Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Annals of Neurology, 2001, 49, 706-711.	2.8	238
8	Myostatin Directly Regulates Skeletal Muscle Fibrosis. Journal of Biological Chemistry, 2008, 283, 19371-19378.	1.6	214
9	Muscle regeneration in the prolonged absence of myostatin. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2519-2524.	3.3	181
10	The 87K postsynaptic membrane protein from torpedo is a protein-tyrosine kinase substrate homologous to dystrophin. Neuron, 1993, 10, 511-522.	3.8	152
11	Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis. Human Molecular Genetics, 2012, 21, 4419-4430.	1.4	150
12	Concordant but Varied Phenotypes among Duchenne Muscular Dystrophy Patient-Specific Myoblasts Derived using a Human iPSC-Based Model. Cell Reports, 2016, 15, 2301-2312.	2.9	141
13	Current treatment of adult Duchenne muscular dystrophy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2007, 1772, 229-237.	1.8	120
14	In Vivo Selection Yields AAV-B1 Capsid for Central Nervous System and Muscle Gene Therapy. Molecular Therapy, 2016, 24, 1247-1257.	3.7	98
15	Telomere position effect regulates DUX4 in human facioscapulohumeral muscular dystrophy. Nature Structural and Molecular Biology, 2013, 20, 671-678.	3.6	95
16	Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics. Molecular Therapy, 2016, 24, 1405-1411.	3.7	90
17	The Paradox of Muscle Hypertrophy in Muscular Dystrophy. Physical Medicine and Rehabilitation Clinics of North America, 2012, 23, 149-172.	0.7	85
18	Inhibiting myostatin reverses muscle fibrosis through apoptosis. Journal of Cell Science, 2012, 125, 3957-65.	1.2	81

#	Article	IF	CITATIONS
19	Transcriptional profiling in facioscapulohumeral muscular dystrophy to identify candidate biomarkers. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16234-16239.	3.3	81
20	Myostatin does not regulate cardiac hypertrophy or fibrosis. Neuromuscular Disorders, 2007, 17, 290-296.	0.3	79
21	Cardiac Management of the Patient With Duchenne Muscular Dystrophy. Pediatrics, 2018, 142, S72-S81.	1.0	77
22	Individual epigenetic status of the pathogenic D4Z4 macrosatellite correlates with disease in facioscapulohumeral muscular dystrophy. Clinical Epigenetics, 2015, 7, 37.	1.8	76
23	A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis. Experimental Neurology, 2009, 217, 258-268.	2.0	75
24	Stem cell-based therapies for Duchenne muscular dystrophy. Experimental Neurology, 2020, 323, 113086.	2.0	74
25	Pathophysiology and Therapy of Cardiac Dysfunction in Duchenne Muscular Dystrophy. American Journal of Cardiovascular Drugs, 2011, 11, 287-294.	1.0	73
26	Regeneration versus fibrosis in skeletal muscle. Current Opinion in Rheumatology, 2011, 23, 568-573.	2.0	73
27	Sildenafil does not improve cardiomyopathy in <scp>D</scp> uchenne/ <scp>B</scp> ecker muscular dystrophy. Annals of Neurology, 2014, 76, 541-549.	2.8	73
28	Therapeutic advances in muscular dystrophy. Annals of Neurology, 2013, 74, 404-411.	2.8	70
29	Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice. Human Molecular Genetics, 2009, 18, 3145-3152.	1.4	68
30	Wholeâ€body magnetic resonance imaging evaluation of facioscapulohumeral muscular dystrophy. Muscle and Nerve, 2015, 52, 512-520.	1.0	63
31	A unique library of myogenic cells from facioscapulohumeral muscular dystrophy subjects and unaffected relatives: family, disease and cell function. European Journal of Human Genetics, 2012, 20, 404-410.	1.4	57
32	AAV9 Edits Muscle Stem Cells in Normal and Dystrophic Adult Mice. Molecular Therapy, 2019, 27, 1568-1585.	3.7	54
33	The care of patients with Duchenne, Becker, and other muscular dystrophies in the <scp>COVID</scp> â€19 pandemic. Muscle and Nerve, 2020, 62, 41-45.	1.0	54
34	Muscle regeneration through myostatin inhibition. Current Opinion in Rheumatology, 2005, 17, 720-724.	2.0	50
35	Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial. Journal of Neuromuscular Diseases, 2021, 8, 989-1001.	1.1	50
36	Human skeletal muscle xenograft as a new preclinical model for muscle disorders. Human Molecular Genetics, 2014, 23, 3180-3188.	1.4	48

#	Article	IF	CITATIONS
37	Long-read single-molecule maps of the functional methylome. Genome Research, 2019, 29, 646-656.	2.4	48
38	Gene expression profiling of skeletal muscles treated with a soluble activin type IIB receptor. Physiological Genomics, 2011, 43, 398-407.	1.0	44
39	Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophy. Science Translational Medicine, 2020, 12, .	5.8	44
40	Reevaluating measures of disease progression in facioscapulohumeral muscular dystrophy. Neuromuscular Disorders, 2013, 23, 306-312.	0.3	41
41	Hydroxychloroquine causes severe vacuolar myopathy in a patient with chronic graft-versus-host disease. American Journal of Hematology, 2005, 78, 306-309.	2.0	40
42	Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy. Neuromuscular Disorders, 2020, 30, 492-502.	0.3	40
43	Approaching a New Age in Duchenne Muscular Dystrophy Treatment. Neurotherapeutics, 2008, 5, 583-591.	2.1	39
44	Genetic diseases of muscle. Neurologic Clinics, 2002, 20, 645-678.	0.8	38
45	Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e172.	3.1	38
46	Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy. Muscle and Nerve, 2017, 55, 333-337.	1.0	37
47	Adipose-derived Stem/Stromal Cells on Electrospun Fibrin Microfiber Bundles Enable Moderate Muscle Reconstruction in a Volumetric Muscle Loss Model. Cell Transplantation, 2018, 27, 1644-1656.	1.2	35
48	Genetic disruption of Smad7 impairs skeletal muscle growth and regeneration. Journal of Physiology, 2015, 593, 2479-2497.	1.3	32
49	Engineering 3D skeletal muscle primed for neuromuscular regeneration following volumetric muscle loss. Biomaterials, 2020, 255, 120154.	5.7	31
50	Results of a two-year pilot study of clinical outcome measures in collagen VI- and laminin alpha2-related congenital muscular dystrophies. Neuromuscular Disorders, 2015, 25, 43-54.	0.3	30
51	Magnetic resonance imaging phenotyping of Becker muscular dystrophy. Muscle and Nerve, 2014, 50, 962-967.	1.0	28
52	Mammalian Mss51 is a Skeletal Muscle-Specific Gene Modulating Cellular Metabolism. Journal of Neuromuscular Diseases, 2015, 2, 371-385.	1.1	28
53	The elusive promise of myostatin inhibition for muscular dystrophy. Current Opinion in Neurology, 2020, 33, 621-628.	1.8	28
54	Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis. Science Translational Medicine, 2022, 14, eabi9196.	5.8	27

#	Article	IF	CITATIONS
55	Identification of the hyaluronic acid pathway as a therapeutic target for facioscapulohumeral muscular dystrophy. Science Advances, 2019, 5, eaaw7099.	4.7	26
56	Left Ventricular Dysfunction and Conduction Disturbances in Patients With Myotonic Muscular Dystrophy Type I and II. JAMA Cardiology, 2017, 2, 225.	3.0	25
57	Cancer Risk in Myotonic Dystrophy Type I: Evidence of a Role for Disease Severity. JNCI Cancer Spectrum, 2018, 2, pky052.	1.4	24
58	A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment. Journal of Neuromuscular Diseases, 2022, 9, 39-52.	1.1	24
59	Tyrosine and Serine Phosphorylation of Dystrophin and the 58â€kDa Protein in the Postsynaptic Membrane of <i>Torpedo</i> Electric Organ. Journal of Neurochemistry, 1994, 62, 1947-1952.	2.1	22
60	Dystrophin-deficient dogs with reduced myostatin have unequal muscle growth and greater joint contractures. Skeletal Muscle, 2016, 6, 14.	1.9	22
61	Duchenne muscular dystrophy hiPSC-derived myoblast drug screen identifies compounds that ameliorate disease in mdx mice. JCl Insight, 2020, 5, .	2.3	22
62	The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development. Orphanet Journal of Rare Diseases, 2015, 10, 49.	1.2	21
63	Facioscapulohumeral Muscular Dystrophies. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 1662-1681.	0.4	21
64	CaMKII oxidation is a critical performance/disease trade-off acquired at the dawn of vertebrate evolution. Nature Communications, 2021, 12, 3175.	5.8	19
65	Improving translatability of preclinical studies for neuromuscular disorders: lessons from the TREAT-NMD Advisory Committee for Therapeutics (TACT). DMM Disease Models and Mechanisms, 2020, 13, .	1.2	18
66	Human muscle stem cells are refractory to aging. Aging Cell, 2021, 20, e13411.	3.0	18
67	Neurology Care, Diagnostics, and Emerging Therapies of the Patient With Duchenne Muscular Dystrophy. Pediatrics, 2018, 142, S5-S16.	1.0	16
68	Benign tumors in myotonic dystrophy type I target diseaseâ€related cancer sites. Annals of Clinical and Translational Neurology, 2019, 6, 1510-1518.	1.7	16
69	Mss51 deletion enhances muscle metabolism and glucose homeostasis in mice. JCI Insight, 2019, 4, .	2.3	16
70	Biological scaffold–mediated delivery of myostatin inhibitor promotes a regenerative immune response in an animal model of Duchenne muscular dystrophy. Journal of Biological Chemistry, 2018, 293, 15594-15605.	1.6	14
71	Diabetes, metformin and cancer risk in myotonic dystrophy type I. International Journal of Cancer, 2020, 147, 785-792.	2.3	13
72	Longitudinal functional and imaging outcome measures in FKRP limb-girdle muscular dystrophy. BMC Neurology, 2020, 20, 196.	0.8	13

#	Article	IF	CITATIONS
73	A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD Trial. Journal of Neuromuscular Diseases, 2021, 8, 769-784.	1.1	13
74	iMyoblasts for ex vivo and in vivo investigations of human myogenesis and disease modeling. ELife, 2022, 11, .	2.8	13
75	The NIH Toolbox for cognitive surveillance in Duchenne muscular dystrophy. Annals of Clinical and Translational Neurology, 2019, 6, 1696-1706.	1.7	12
76	A decade of optimizing drug development for rare neuromuscular disorders through TACT. Nature Reviews Drug Discovery, 2020, 19, 1-2.	21.5	12
77	Human pluripotent stem cell-derived myogenic progenitors undergo maturation to quiescent satellite cells upon engraftment. Cell Stem Cell, 2022, 29, 610-619.e5.	5.2	10
78	Homeâ€based gait analysis as an exploratory endpoint during a multicenter phase 1 trial in limb girdle muscular dystrophy type <scp>R2</scp> and facioscapulohumeral muscular dystrophy. Muscle and Nerve, 2022, 65, 237-242.	1.0	8
79	Randomized phase 2 study of <scp>ACE</scp> â€083, a <scp>muscleâ€promoting</scp> agent, in facioscapulohumeral muscular dystrophy. Muscle and Nerve, 2022, 66, 50-62.	1.0	8
80	Clinical practice considerations in facioscapulohumeral muscular dystrophy Sydney, Australia, 21 September 2015. Neuromuscular Disorders, 2016, 26, 462-471.	0.3	7
81	Safety and disease monitoring biomarkers in Duchenne muscular dystrophy: results from a Phase II trial. Biomarkers in Medicine, 2021, 15, 1389-1396.	0.6	7
82	Bone health in facioscapulohumeral muscular dystrophy: A crossâ€sectional study. Muscle and Nerve, 2017, 56, 1108-1113.	1.0	6
83	Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy: a phase 2 trial of domagrozumab. Journal of Neurology, 2022, 269, 4421-4435.	1.8	6
84	Fast skeletal muscle troponin activator in the dy2J muscular dystrophy model. Muscle and Nerve, 2013, 48, 279-285.	1.0	5
85	A phase Ib/IIa, openâ€label, multiple ascendingâ€dose trial of domagrozumab in fukutinâ€related protein limbâ€girdle muscular dystrophy. Muscle and Nerve, 2021, 64, 172-179.	1.0	5
86	<i>Mss51</i> deletion increases endurance and ameliorates histopathology in the <i>mdx</i> mouse model of Duchenne muscular dystrophy. FASEB Journal, 2021, 35, e21276.	0.2	4
87	It's not all about muscle: fibroadipogenic progenitors contribute to facioscapulohumeral muscular dystrophy. Journal of Clinical Investigation, 2020, 130, 2186-2188.	3.9	3
88	Clinical Applications of Myostatin Inhibitors for Neuromuscular Diseases. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2010, 10, 204-210.	0.5	2
89	Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice. Journal of Visualized Experiments, 2019, , .	0.2	2
90	Quantitative Muscle Analysis in Facioscapulohumeral Muscular Dystrophy Using <scp>Wholeâ€Body Fatâ€Referenced MRI</scp> : Protocol Development, Multicenter Feasibility, and Repeatability. Muscle and Nerve, 2022, , .	1.0	1

#	Article	IF	CITATIONS
91	The state of the field: myology. Current Opinion in Neurology, 2009, 22, 498-499.	1.8	Ο